| Literature DB >> 31638346 |
Patricia Renz1, Elias Imahorn1, Iris Spoerri1, Magomet Aushev2, Oliver P March3, Hedwig Wariwoda1, Sarah Von Arb1, Andreas Volz4, Peter H Itin1,4, Julia Reichelt3, Bettina Burger1.
Abstract
Ichthyosis with confetti (IWC) is a genodermatosis associated with dominant-negative variants in keratin 10 (KRT10) or keratin 1 (KRT1). These frameshift variants result in extended aberrant proteins, localized to the nucleus rather than the cytoplasm. This mislocalization is thought to occur as a result of the altered carboxy (C)-terminus, from poly-glycine to either a poly-arginine or -alanine tail. Previous studies on the type of C-terminus and subcellular localization of the respective mutant protein are divergent. In order to fully elucidate the pathomechanism of IWC, a greater understanding is critical. This study aimed to establish the consequences for localization and intermediate filament formation of altered keratin 10 (K10) C-termini. To achieve this, plasmids expressing distinct KRT10 variants were generated. Sequences encoded all possible reading frames of the K10 C-terminus as well as a nonsense variant. A keratinocyte line was transfected with these plasmids. Additionally, gene editing was utilized to introduce frameshift variants in exon 6 and exon 7 at the endogenous KRT10 locus. Cellular localization of aberrant K10 was observed via immunofluorescence using various antibodies. In each setting, immunofluorescence analysis demonstrated aberrant nuclear localization of K10 featuring an arginine-rich C-terminus. However, this was not observed with K10 featuring an alanine-rich C-terminus. Instead, the protein displayed cytoplasmic localization, consistent with wild-type and truncated forms of K10. This study demonstrates that, of the various 3' frameshift variants of KRT10, exclusively arginine-rich C-termini lead to nuclear localization of K10.Entities:
Keywords: KRT10; alanine-rich C-terminus; arginine-rich C-terminus; carboxy terminus; ichthyosis with confetti; keratin 10; nuclear localization
Mesh:
Substances:
Year: 2019 PMID: 31638346 PMCID: PMC6850952 DOI: 10.1111/jcmm.14727
Source DB: PubMed Journal: J Cell Mol Med ISSN: 1582-1838 Impact factor: 5.310
Overview of reported patients with IWC
| No of patients | No of families | Sex | Clinically described | Without spots | Affected gene | Type of variant | Reference | ||
|---|---|---|---|---|---|---|---|---|---|
| Male | Female |
|
| ||||||
| 1* | 1 | 1 | 1 | Unknown |
| ||||
| 1* | 1 | 1 | 1 | Unknown |
| ||||
| 1* | 1 | 1 | 1 | Unknown |
| ||||
| 1* | 1 | 1 | 1 | Unknown |
| ||||
| 1* | 1 | 1 | 1 | Unknown |
| ||||
| 1* | 1 | 1 | 1 | Unknown |
| ||||
|
|
|
|
|
| |||||
| 1 | 1 | 1 | 1 | c.1370G>T | Exon 6 |
| |||
| 1 | 1 | 1 | 1 | c.1373+1delG | Donor splice site |
| |||
| 3 | 1 | 2 | 1 | c.1373+1G>A | Donor splice site |
| |||
| 3 | 1 | 1 | 2 | 3 | 2 | c.1373+1G>C | Donor splice site |
| |
| 1 | 1 | 1 | 1 | c.1373+2T>C | Donor splice site |
| |||
| 1 | 1 | 1 | c.1374‐2delA | Acceptor splice site |
| ||||
| 1 | 1 | 1 | 1 | 1 | c.1374‐2A>C | Acceptor splice site |
| ||
| 2 | 2 | 2 | 1 | c.1374‐2A>G | Acceptor splice site |
| |||
| 4 | 3 | 1 | 2 | 2 | c.1374‐1G>A | Acceptor splice site |
| ||
| 5 | 5 | 3 | 3 | 6 | 1 | c.1374‐1G>C | Acceptor splice site |
| |
| 1 | 1 | 1 | 1 | c.1383_1414del | Exon 7 |
| |||
| 1 | 1 | 1 | 1 | c.1411_1412insA | Exon 7 |
| |||
| 1 | 1 | 1 | c.1449_1450insC | Exon 7 |
| ||||
| 1 | 1 | 1 | 1 | c.1452_1464delinsAG | Exon 7 |
| |||
| 1 | 1 | 1 | 1 | c.1506_1507del | Exon 7 |
| |||
| 2 | 2 | 2 | 2 | c.1544dupG | Exon 7 |
| |||
| 1 | 1 | 1 | 1 | c.1546_1551delinsT | Exon 7 |
| |||
| 1 | 1 | 1 | 1 | c.1557_1558delCG | Exon 7 |
| |||
| 2 | 1 | 1 | 1 | c.1560_1561delGC | Exon 7 |
| |||
| 2 | 1 | 2 | 1 | c.1573dupA | Exon 7 |
| |||
|
|
|
|
|
|
|
|
| ||
| 6 | 1 | 2 | 4 | 5 | 3 | c.591+329_1129‐37del | Exon 9 |
| |
| 1 | 1 | 1 | 1 | 1 | c.1756_1757insG | Exon 9 |
| ||
| 1 | 1 | 1 | 1 | 1 | c.1752dupT | Exon 9 |
| ||
| 3 | 1 | 1 | 2 | 3 | 1 | c.1758_1759insT | Exon 9 |
| |
| 1 | 1 | 1 | 1 | 1 | c.1860_1861insT | Exon 9 |
| ||
| 4 | 1 | 4 | 4 | c.1865_1866insG | Exon 9 |
| |||
|
|
|
|
|
|
|
|
| ||
All IWC patients carry heterozygous variants in KRT10 (NM_000421) or KRT1 (NM_006121). Two variants, originally described as a poly‐alanine reading frame, have been redefined according to HGVS nomenclature (indicated by †† and ‡). Six patients, which have not been sequenced but displayed typical IWC clinical features, including pale spots, are also listed (indicated by *). Data include eleven patients from different families who have not currently developed pale spots but carry a poly‐arginine tail‐causing frameshift variant. Of these, three siblings in a familial IWC resembled epidermolytic ichthyosis (EI) (indicated by a). Three sporadic cases were clinically described as EI (indicated by b) or ichthyosis hystrix Curth‐Macklin (IHCM) (indicated by c).
Resembled epidermolytic ichthyosis (EI).
Described as epidermolytic hyperkeratosis, renamed as epidermolytic ichthyosis (EI) (OMIM #113800).
Described as ichthyosis hystrix Curth‐Macklin (OMIM #146590).
Originally described as c.1369G>T; results in a new donor splice site.
Originally described as c.1373delG (alanine‐rich C‐terminus).
Originally described as c.1751insG.
One of them initially described as c.1544delG (alanine‐rich C‐terminus).
Figure 1Products amplified from total KRT10 mRNA of NKc21 cells after transfection with either wild‐type or IWC‐associated KRT10 gDNA. A. PCR‐amplified cDNA product, following transfection of NKc21 cells with wild‐type plasmid (p1_wt_g_GFP), was at the expected wild‐type size (~2.1 kb). Transfection with IWC‐associated KRT10 gDNA (p4_var_g_GFP) resulted in four major products, of distinct sizes (~2.4, ~2.1, ~1.9 and ~1.8 kb). Each product was cloned into pEGFP‐C1 for further studies. B. Unsaturated PCR following RT‐PCR of transcripts after transfection with p4_var_g_GFP, using primers localized in exon 6 and 7. These only amplify the 2.1 kb products. Separation of the resulting products (3130xl Genetic Analyzer, Applied Biosystems) showed peaks at 272 bp (arg_s) and 276 bp (ala_s). Measurement of the area under the curve (ht) revealed the quantity of PCR product, almost double the amount of the 4 bp shorter KRT10 (arg_s, r.1369_1373del) vs. KRT10 (ala_s, r.1373del) PCR product. Red triangles indicate the size marker (GeneScan™ 500 ROX™ (ThermoFisher Scientific Inc))
Figure 2Localization of K10 following transient transfection of NKc21 keratinocytes with K10wt encoding plasmids. K10 was detected either by imaging the eGFP fluorescence expressed from plasmid (cellular eGFP, green) or immunostaining with anti‐K10 antibody DE‐K10 (orange). The nuclear membrane was labelled with an anti‐lamin antibody (red). DAPI (blue) was used for nuclear staining. All K10 constructs: KRT10 wild‐type gDNA (p1_wt_g_GFP), the corresponding cDNA (p3_wt_s_GFP) or cDNA from a wild‐type control (p2_wt_c_GFP) carried an N‐terminal eGFP‐tag. Antibodies against K10 and lamin showed clear cytoplasmic localization in every wild‐type K10. Scale bar, 5 μm
Figure 3Localization of K10 following transient transfection of NKc21 keratinocytes with K10arg encoding plasmids. K10 was detected either by imaging of eGFP expressed from plasmid (cellular eGFP, green) or immunostaining with an anti‐K10 antibody (DE‐K10, orange). The nuclear membrane was labelled with an anti‐lamin antibody (red). DAPI (blue) was used for nuclear staining. All K10 constructs: IWC‐causing KRT10 gDNA (p4_var_g_GFP), the corresponding cDNA from splice products (p6_arg_s_GFP, p9_arg_s_GFP) and patient cDNA (p5_arg_c_GFP) carried an N‐terminal eGFP‐tag. The expressed K10 was localized in the nucleus of transfected keratinocytes. Scale bar, 5 μm
Figure 4Localization of K10 following transient transfection of NKc21 keratinocytes with K10ala‐ or K10ter‐encoding plasmids. K10 was detected either by imaging of eGFP expressed from plasmid (cellular EGFP, green) or immunostaining with an anti‐K10 (DE‐K10) or anti‐GFP antibody (both orange). The nuclear membrane was labelled with an anti‐lamin antibody (red). DAPI (blue) was used for nuclear staining. All K10ala (p10_ala_c_GFP, p11_ala_s_GFP) or K10ter (p13_ter_c_GFP, p14_ter_s_GFP) carried an N‐terminal EGFP‐tag. K10arg and K10ter were both exclusively localized in the cytoplasm. As the aberrant K10 in p11_ala_s_GFP and p14_ter_s_GFP could not be detected with the DE‐K10 antibody, the anti‐GFP antibody was used for staining. Scale bar, 5 μm
Figure 5Epidermal equivalents derived from gene edited NKc21 single‐cell clones expressing K10ala displayed thin epithelium. Haematoxylin and eosin staining of epidermal models. Epidermal equivalents derived from wild‐type (A), mock control (B), and heterozygous K10arg clones (C) displayed a differentiated epithelium including basal layer and stratum spinosum (orange bar). Epidermal equivalents derived from K10ala clones demonstrated a thin epithelium (D). All shown clones were cultivated in parallel, epidermal equivalents C and D are derived from clones e4_arg_26‐1 (K10arg) and e6_ala_26‐1 (K10ala). Parakeratosis was observed in all samples (black arrows). The supporting filter membrane is indicated (green bar). Scale bar (black), 20 μm
Figure 6Epidermal equivalents derived from K10arg keratinocyte single‐cell clones display nuclear localization of K10 in differentiated suprabasal layers. Immunofluorescence staining via N‐ (LH2, exact binding region unknown; red) and C‐terminus‐specific (EP1607IHCY, amino acids 555‐584; green) K10 antibodies indicated nuclear localization of K10 in the suprabasal keratinocytes of K10arg‐derived equivalents (white arrowhead). In K10wt‐ or K10ala‐derived equivalents, K10 was localized exclusively in the cytoplasm. Nuclear co‐translocation of endogenous K10wt and K10arg (e4_arg_26‐1) enabled observation of nuclear localization via the C‐terminus‐specific anti‐K10 (white arrowhead). DAPI (blue) was used for nuclear staining. Border between supporting filter membrane and basal layer indicated (white‐dotted line). Scale bar, 20 μm